Use of Recombinant Human Deoxyribonuclease in Pediatric Intensive Care Unit - a Single-center Experience

Overview

Journal Rev Paul Pediatr

Specialty Pediatrics

Date 2021 Sep 8

PMID 34495270

Authors

Daniel Meireles

Sofia Ribeiro Fernandes

Alzira Sarmento

Telma Barbosa

Manuel Ferreira Magalhaes

Ana Ramos

Paula Cristina Fernandes

Affiliations

Soon will be listed here.

Abstract

Objective: Dornase alfa (rhDNase) reduces the viscosity of purulent sputum in the lungs. The use in patients with cystic fibrosis (CF) is proven. However, the evidence of its applicability to other conditions is limited. This study aims to present the authors' experience with the use of rhDNase in non-CF patients admitted to the Pediatric Intensive Care Unit (PICU). At the study center, rhDNase was used during flexible bronchoscopies in 24 cases, of which 20 (83%) had atelectasis and seven (29%) were admitted to PICU. Four patients (57%) were on invasive mechanical ventilation (MV).

Case Description: Two cases of daily rhDNase administration at PICU are presented: patient A was an 8-year-old boy admitted with septic shock and acute respiratory distress syndrome (ARDS). The patient required mechanical ventilation with aggressive settings and experienced several clinical complications. On D50, he started rhDNase treatment with an improvement in FiO2, PaCO2 and PaO2/FiO2 ratio according to radiologic findings. He was extubated on D23 of treatment.Patient B was a 17-month-old girl admitted with a convulsive status epilepticus who experienced respiratory complications (infectious and barotrauma) with ARDS, requiring aggressive ventilation. She initiated rhDNase treatment on D60. During the treatment an improvement in FiO2, PaO2/FiO2 ratio and a tendency of PaCO2 decrease were found. She had radiological improvement. No complications were described.

Comments: RhDNase may be a helpful and safe tool to use in PICU prolonged intubated patients with ventilator-induced lung injury. Further studies are needed to assess and propose valid indications.

References

Rivera R, Tibballs J . Complications of endotracheal intubation and mechanical ventilation in infants and children. Crit Care Med. 1992; 20(2):193-9. DOI: 10.1097/00003246-199202000-00008. View

Yang C, Montgomery M . Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018; 9:CD001127. PMC: 6513278. DOI: 10.1002/14651858.CD001127.pub4. View

Boeuf B, Prouix F, Morneau S, Marton D, Lacroix J . Safety of endotracheal rh DNAse (Pulmozyme) for treatment of pulmonary atelectasis in mechanically ventilated children. Pediatr Pulmonol. 1998; 26(2):147. DOI: 10.1002/(sici)1099-0496(199808)26:2<147::aid-ppul14>3.0.co;2-1. View

Papacostas M, Luckett P, Hupp S . The use of pulmonary clearance medications in the acutely ill patient. Expert Rev Respir Med. 2017; 11(10):815-826. DOI: 10.1080/17476348.2017.1358089. View

Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M . Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol. 2005; 41(1):61-6. DOI: 10.1002/ppul.20298. View

Prodhan P, Greenberg B, Bhutta A, Hyde C, Vankatesan A, Imamura M . Recombinant human deoxyribonuclease improves atelectasis in mechanically ventilated children with cardiac disease. Congenit Heart Dis. 2009; 4(3):166-73. PMC: 2997270. DOI: 10.1111/j.1747-0803.2009.00289.x. View

Enriquez A, Chu I, Mellis C, Lin W . Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months. Cochrane Database Syst Rev. 2012; 11:CD008395. PMC: 7388903. DOI: 10.1002/14651858.CD008395.pub2. View

Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L . Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009; 23(1-3):205-10. DOI: 10.1159/000204109. View

Yang C, Chilvers M, Montgomery M, Nolan S . Dornase alfa for cystic fibrosis. Paediatr Respir Rev. 2016; 21:65-67. DOI: 10.1016/j.prrv.2016.09.001. View

10.

El Hassan N, Chess P, Huysman M, Merkus P, de Jongste J . Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics. 2001; 108(2):468-70. DOI: 10.1542/peds.108.2.468. View

11.

Hendriks T, de Hoog M, Lequin M, Devos A, Merkus P . DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care. 2005; 9(4):R351-6. PMC: 1269442. DOI: 10.1186/cc3544. View

12.

Fedakar A, Aydogdu C, Fedakar A, Ugurlucan M, Bolu S, Iskender M . Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns. Ann Saudi Med. 2012; 32(2):131-6. PMC: 6086641. DOI: 10.5144/0256-4947.2012.131. View

13.

Armstrong J, White J . Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet. 1950; 2(6641):739-42. DOI: 10.1016/s0140-6736(50)91676-x. View

14.

Strickland S, Rubin B, Haas C, Volsko T, Drescher G, OMalley C . AARC Clinical Practice Guideline: Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients. Respir Care. 2015; 60(7):1071-7. DOI: 10.4187/respcare.04165. View

15.

Merkus P, de Hoog M, van Gent R, de Jongste J . DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J. 2001; 18(4):734-7. View

16.

Voelker K, Chetty K, Mahutte C . Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase. Intensive Care Med. 1996; 22(6):582-4. DOI: 10.1007/BF01708100. View